iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced that its CEO, Michel Detheux, will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:00 a.m. ET. The topic will focus on opportunities and challenges in immuno-oncology.
A live webcast can be accessed on the company's website, with an archived replay available for 30 days post-event. iTeos is developing innovative immuno-oncology therapeutics, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing the immune response against cancer.
- None.
- None.
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs Wide Open – Opportunities and Challenges in Immuno-Oncology” on Tuesday, August 9, 2022 at 8:00 a.m. ET.
A live webcast of the events will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contacts:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
What is the date of the panel discussion featuring Michel Detheux from iTeos Therapeutics?
What is the focus of the panel discussion at the Wedbush PacGrow Healthcare Conference?
Where can I watch the iTeos Therapeutics panel discussion live?
What innovative products is iTeos Therapeutics developing?
What is the stock symbol for iTeos Therapeutics?
